Faculty

Institution

Unit

Venue

William G. Wierda, M.D., Ph.D.

The University of Texas MD Anderson Cancer Center

Affiliations

Section Of Molecular Hematology And Therapy

Department Of Leukemia

William G. Wierda, M.D., Ph.D., is a Professor of Medicine and High Senior Professor in the Department of Leukemia at The University of Texas MD Anderson Cancer Center. His research focuses on the biology and treatment of chronic lymphocytic leukemia (CLL), Richter transformation, and B-cell acute lymphoblastic leukemia, with specific interests in targeted therapies, BTK inhibitors, and chemoimmunotherapy combinations. He leads international trials including ELEVATE-TN and ZUMA-3, and has published on genomic determinants of resistance to pirtobrutinib and CLL exosome-mediated immune modulation. He co-authored the ERIC international consensus on Richter transformation and has contributed extensively to hematological oncology.

Honors

Create free account to unlock more features

Experiences

Create free account to unlock more features

Education

Create free account to unlock more features

William G. Wierda, M.D., Ph.D.

The University of Texas MD Anderson Cancer Center

You can click a keyword to filter the displayed items

oncology hematology medicine leukemia immunology hematological malignancies pharmacology cancer research cancer treatment lymphoid neoplasia pharmacotherapy medicinal research cancer immunotherapy cancer care chronic lymphocytic leukemia immunotherapy clinical research cellular therapy clinical trials oncogenes tumor biology clinical transplantation genetics myeloid neoplasia laboratory medicine malignant blood disorders cancer cells cancer biology bone marrow transplantation cancer management anti-cancer agents clinical immunology cell therapy jama oncology molecular cancer cell death therapeutic efficacy hemostasis chronic myeloid leukemia disease progression acute myeloid leukemia experimental medicine cancer genetics surgical oncology phase ii study prognosis thrombosis cancer genomics cohort studies anticoagulants blood transfusion treatment development apoptosis cell regulation clinical mycology novel therapies adult patients chronic lymphocytic leukaemia treatment options receptor tyrosine kinases cord blood tumor targeting richter transformation chronic phase first-line treatment immunohaematology malignant disease treatment effects initial therapy lisocabtagene maraleucel long-term follow-up inotuzumab ozogamicin treatment and prevention chronic myelogenous leukemia untreated patients lymphocytic leukemia cancer letter lung cancer autoimmune diseases cell biology surgical pathology autoimmunity cell transplantation therapeutic targets carcinogenesis metastasis urology molecular diagnostics sarcoma histopathology internal medicine tumor microenvironment cancer discovery translational medicine radiation oncology individualized medicine molecular medicine gynecologic oncology haematopoiesis dermatology thoracic oncology translational research health sciences pathology

Notable Scholarly Works

Notable Federal Grants

Collaborators

71 | Final Analysis of Fixed‐Duration Ibrutinib + Venetoclax for Chronic Lymphocytic Leukemia (Cll)/Small Lymphocytic Lymphoma (Sll) in the Phase 2 Captivate Study. Hematological Oncology (2025)

hematologyoncologyleukemialymphoid neoplasiapharmacotherapypathology

Abstract B126: The Effects of Amaryllidaceae Plant Constituents Narciclasine, Lycorine and Haemanthamine on Chronic Lymphocytic Leukemia Cells. Molecular Cancer Therapeutics (2025)

Abstract P83: The Change of Partners in Apoptosis Induction in the Cll Cells. Cancer Research (2025)

molecular and cellular biologycell divisioncell biologymolecular cell biologycell signalingautophagyoncogenesleukemiaimmunologycell researchcell and molecular biologysignal transductionmolecular medicinemolecular biologycarcinogenesiscell deathcellular biochemistry

Acalabrutinib-Obinutuzumab Improves Survival vs Chemoimmunotherapy in Treatment-Naive Cll in the 6-Year Follow-Up of Elevate-Tn. Blood (2025)

hematologymedicineoncologyhematological malignanciesleukemiaimmunotherapyimmunologyexperimental medicinepharmacotherapytherapeutic efficacy

Addition of Obinutuzumab After One Year of Combined Acalabrutinib and Venetoclax is Safer and Effective Than Early Obinutuzumab in a Randomized Phase II Trial for Treatment NaïVe Cll. Blood (2025)

medicineoncologyclinical therapeuticssystemic treatmentcombined acalabrutinibimmunologypharmacologyapplied pharmacologytherapeutic targetscancer treatmenttreatment naïve cllexperimental medicinepharmacotherapyclinical trials

A Multiarm Phase 1B Study of Personalized Oral Maintenance Therapy With Decitabine/Cedazuridine (Astx727) Plus Physician's Choice of Venetoclax, Gilteritinib, Enasidenib, or Ivosidenib in Acute Myeloid Leukemia. Blood (2025)

hematologymedicineoncologyhematological malignanciesmyeloid neoplasialeukemiamultiarm phase 1bpharmacologyapplied pharmacologyindividualized medicineclinical researchpharmacotherapyacute myeloid leukemiaclinical trials

A Tour of Leukemia Progress in 2025, Viewed Through the MD Anderson Leukemia Research Lens. Cancer (2025)

hematologyleukemia progressmedicinecancer researchradiation oncologyoncologyhematological malignanciesmyeloid neoplasiamd andersonleukemiamalignant blood disorderscancer careresearch lenstranslational researchmixed-phenotype acute leukemia

Blinatumomab and Ponatinib vs. Hyper-Cvad and Ponatinib in Patients With Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia: A Propensity Score Analysis. Blood (2025)

hematologymedicineoncologyhematological malignanciesleukemiabone marrow transplantationmalignant blood disorderspropensity score analysispathology

Brexucabtagene Autoleucel (Brexu-Cel) as Consolidation Treatment in Adults With B-Cell Acute Lymphoblastic Leukemia.. Journal of Clinical Oncology (2025)

hematologytranslational medicinemedicineoncologyhematological malignanciesadult t-cell leukemia-lymphomaconsolidation treatmentleukemiabone marrow transplantationimmunotherapylymphoid neoplasiabrexucabtagene autoleucelpathology

Clinical Features and Occurrence of Other Cancers in Patients With Chronic Lymphocytic Leukemia and Their Families With Pot1 Tumor Predisposition Syndrome.. Journal of Clinical Oncology (2025)

tumor biologyoncologyradiation oncologycancer researchhistopathologyhematological malignanciesleukemiaoncogeneslymphoid neoplasiaother cancerschronic lymphocytic leukemiaclinical featurespathology

1
2
3
4
5
130
10 / page

William G. Wierda, M.D., Ph.D.

The University of Texas MD Anderson Cancer Center

Affiliations

Section Of Molecular Hematology And Therapy

Department Of Leukemia

Honors

Create free account to unlock more features

Experiences

Create free account to unlock more features

Education

Create free account to unlock more features

William G. Wierda, M.D., Ph.D.

The University of Texas MD Anderson Cancer Center

You can click a keyword to filter the displayed items

Notable Scholarly Works

Notable Federal Grants

Collaborators

71 | Final Analysis of Fixed‐Duration Ibrutinib + Venetoclax for Chronic Lymphocytic Leukemia (Cll)/Small Lymphocytic Lymphoma (Sll) in the Phase 2 Captivate Study. Hematological Oncology (2025)

hematologyoncologyleukemialymphoid neoplasiapharmacotherapypathology

Abstract B126: The Effects of Amaryllidaceae Plant Constituents Narciclasine, Lycorine and Haemanthamine on Chronic Lymphocytic Leukemia Cells. Molecular Cancer Therapeutics (2025)

Abstract P83: The Change of Partners in Apoptosis Induction in the Cll Cells. Cancer Research (2025)

Acalabrutinib-Obinutuzumab Improves Survival vs Chemoimmunotherapy in Treatment-Naive Cll in the 6-Year Follow-Up of Elevate-Tn. Blood (2025)

hematologymedicineoncologyhematological malignanciesleukemiaimmunotherapyimmunologyexperimental medicinepharmacotherapytherapeutic efficacy

Addition of Obinutuzumab After One Year of Combined Acalabrutinib and Venetoclax is Safer and Effective Than Early Obinutuzumab in a Randomized Phase II Trial for Treatment NaïVe Cll. Blood (2025)

A Tour of Leukemia Progress in 2025, Viewed Through the MD Anderson Leukemia Research Lens. Cancer (2025)

Blinatumomab and Ponatinib vs. Hyper-Cvad and Ponatinib in Patients With Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia: A Propensity Score Analysis. Blood (2025)

hematologymedicineoncologyhematological malignanciesleukemiabone marrow transplantationmalignant blood disorderspropensity score analysispathology

Brexucabtagene Autoleucel (Brexu-Cel) as Consolidation Treatment in Adults With B-Cell Acute Lymphoblastic Leukemia.. Journal of Clinical Oncology (2025)

Clinical Features and Occurrence of Other Cancers in Patients With Chronic Lymphocytic Leukemia and Their Families With Pot1 Tumor Predisposition Syndrome.. Journal of Clinical Oncology (2025)

tumor biologyoncologyradiation oncologycancer researchhistopathologyhematological malignanciesleukemiaoncogeneslymphoid neoplasiaother cancerschronic lymphocytic leukemiaclinical featurespathology

1
2
3
4
5
130
10 / page